To test cisplatin ability to induce SBS35 mutational signature in hepatoblastoma, 6 pediatric liver tumor cell lines were treated with 0.5μM cisplatin for 4 weeks. At day0, 60 000 cells were seeded in a 6-well plate and reseeded each week at the same concentration. When mortality was too high, cells were not split and fresh medium supplemented with 0.5μM cisplatin was added. At day28, cells were grown in fresh DMEM and limit dilutions were performed in order to expand clonal cell lines. After amplification, samples were extracted using Allprep DNA/RNA/miRNA universal extraction kit (Qiagen). Finally, mutational signature analysis was performed on cells derived from limit dilution and compared with bulk non-treated baseline mutational profile.
Allprep dna rna mirna universal extraction kit
Manufactured by Qiagen
The Allprep DNA/RNA/miRNA Universal Extraction Kit is a laboratory tool designed for the simultaneous purification of genomic DNA, total RNA, and microRNA (miRNA) from a single biological sample. The kit utilizes a streamlined protocol to efficiently extract these different biomolecules from a variety of sample types.
Automatically generated - may contain errors
Lab products found in correlation
2 protocols using allprep dna rna mirna universal extraction kit
1
Inducing SBS35 Signature in Hepatoblastoma
2
Longitudinal Liquid Biopsy Profiling
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Peripheral blood plasma was collected as part of an institutional liquid biopsy collection study, Liquid Biopsy Evaluation and Repository Development at Princess Margaret (LIBERATE) (NCT03702309). Samples were collected before cycles 1, 2 and 3 (each cycle is every 3 or 4 weeks depending on treatment regime), and at the time of disease progression, corresponding to timepoints (T) 1-4. T1 was considered baseline, prior to treatment initiation. At each collection time point, 30 ml of peripheral blood was collected in Cell-Free DNA (cfDNA) BCT RUO tubes (Streck, La Vista, NE). Plasma was separated from the cell pellet within 2 h of collection and aliquoted for storage at -80 °C. cfDNA was purified from clarified plasma using the QIAamp Circulating Nucleic Acid Kit (Qiagen, Hilden, Germany). Peripheral blood leucocyte (PBL) genomic DNA was extracted using the AllPrep DNA/RNA/miRNA Universal Extraction Kit (Qiagen). All cfDNA samples were collected and processed by the Translational Genomics Programme at the Ontario Institute for Cancer Research (Toronto, Canada).
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!